Investigating how certain prostate cancer cells survive and spread in the bones
Interleukin-1beta and AR-negative tumor cells in metastatic castrate-resistant prostate cancer
This study is looking at how certain prostate cancer cells that don't need hormones to grow can survive and help other cancer cells in the bones, especially after standard treatments stop working, and it aims to find new ways to help patients with advanced prostate cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Drexel University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10904712 on NIH RePORTER |
What this research studies
This research focuses on understanding how some prostate cancer cells, which do not rely on the Androgen Receptor (AR), manage to survive and promote the growth of other cancer cells in the bones, especially after androgen-deprivation therapies fail. The study will explore the role of Interleukin-1β (IL-1β) in supporting these AR-negative cancer cells and how they interact with the bone environment. By using animal models, human cell lines, and patient-derived tissues, the researchers aim to uncover the mechanisms that allow these cells to thrive in a challenging environment. The findings could lead to new therapeutic strategies for patients with advanced prostate cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with metastatic castrate-resistant prostate cancer, particularly those with bone metastases.
Not a fit: Patients with early-stage prostate cancer or those whose cancer is not metastatic may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients with metastatic castrate-resistant prostate cancer, potentially improving survival and quality of life.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways in cancer treatment, suggesting that this approach could be effective.
Where this research is happening
Philadelphia, United States
- Drexel University — Philadelphia, United States (Active)
Researchers
- Principal investigator: Fatatis, Alessandro — Drexel University
- Study coordinator: Fatatis, Alessandro
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.